Cannabidiol 20 mg/kg/day and 10 mg/kg/day probably increased the frequency of participants who achieved a ≥50% reduction in monthly seizures (20 mg/kg/day: RR 1.92; 95% CI 1.49–2.46; 10 mg/kg/day: RR 1.94; 95% CI 1.32–2.86, moderate certainty). The incidence of serious adverse events is probably increased with CBD 20 mg/kg/day (RR 2.30; 95% CI 1.36–3.89, moderate certainty).
Endocannabinoid System Research: Cannabinoids in Pediatrics
Clinical Takeaway Cannabinoid treatments in children have been studied across a range of medical conditions, with evidence drawn from hundreds of studies including clinical trials and observational reports. The current body of...
Endocannabinoid System Research: Cannabinoids in Pediatric Care
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence spanning interventional trials, observational studies, and patient surveys. The available data suggest potential benefits in certain conditions...
Endocannabinoid System Research: Cannabis in Pediatric Care
Clinical Takeaway Cannabinoids have been studied across a wide range of pediatric medical conditions, with the current evidence base drawing from both interventional trials and real-world observational data. The strongest and most...
Endocannabinoid System Research: Cannabinoids in Pediatrics
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence spanning interventional trials, observational studies, and patient surveys. The current body of research supports cautious clinical consideration...
Endocannabinoid System Research: Cannabinoids for Children
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence drawn from interventional trials, observational studies, and surveys. The current body of research supports cautious clinical consideration...